245 related articles for article (PubMed ID: 31072235)
61. Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma.
Alacacioglu I; Ozcan MA; Ozkal S; Piskin O; Turgut N; Demirkan F; Ozsan GH; Kargi A; Undar B
Hematology; 2009 Apr; 14(2):84-9. PubMed ID: 19298719
[TBL] [Abstract][Full Text] [Related]
62. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
[TBL] [Abstract][Full Text] [Related]
63. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
Wen J; Zhou J; Liu Z; Liu T; Xu C
Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
[TBL] [Abstract][Full Text] [Related]
64. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
[TBL] [Abstract][Full Text] [Related]
65. Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
Batlle-López A; González de Villambrosía S; Francisco M; Malatxeberria S; Sáez A; Montalban C; Sánchez L; Garcia J; González-Barca E; López-Hernández A; Ruiz-Marcellan MC; Mollejo M; Grande C; Richards KL; Hsi ED; Tzankov A; Visco C; Xu-Monette ZY; Cao X; Young KH; Piris MÁ; Conde E; Montes-Moreno S
Oncotarget; 2016 Apr; 7(14):18036-49. PubMed ID: 26910115
[TBL] [Abstract][Full Text] [Related]
66. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities.
Kano R; Masaie H; Hino A; Yasuoka H; Nagata S; Ishikawa J; Nakatsuka SI
Diagn Pathol; 2018 Jul; 13(1):46. PubMed ID: 30041681
[TBL] [Abstract][Full Text] [Related]
67. High expression of REV7 is an independent prognostic indicator in patients with diffuse large B-cell lymphoma treated with rituximab.
Okina S; Yanagisawa N; Yokoyama M; Sakurai Y; Numata Y; Umezawa A; Higashihara M; Murakumo Y
Int J Hematol; 2015 Dec; 102(6):662-9. PubMed ID: 26449786
[TBL] [Abstract][Full Text] [Related]
68. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.
Nowakowski GS; LaPlant B; Macon WR; Reeder CB; Foran JM; Nelson GD; Thompson CA; Rivera CE; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Gascoyne RD; Habermann TM; Witzig TE
J Clin Oncol; 2015 Jan; 33(3):251-7. PubMed ID: 25135992
[TBL] [Abstract][Full Text] [Related]
69. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
70. Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.
Serag El-Dien MM; Abdou AG; Asaad NY; Abd El-Wahed MM; Kora MAEM
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):534-542. PubMed ID: 26862953
[TBL] [Abstract][Full Text] [Related]
71. Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
Chang ST; Chen SW; Ho CH; Kuo CC; Sakata S; Takeuchi K; Chuang SS
J Formos Med Assoc; 2016 Nov; 115(11):961-967. PubMed ID: 27773559
[TBL] [Abstract][Full Text] [Related]
72. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
73. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
74. MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
Kim S; Nam SJ; Kwon D; Kim H; Lee E; Kim TM; Heo DS; Park SH; Kim CW; Jeon YK
BMC Cancer; 2016 Jun; 16():363. PubMed ID: 27286976
[TBL] [Abstract][Full Text] [Related]
75. [Nodal versus extranodal diffuse large B-cell lymphoma: comparison of clinicopathologic features, immunophenotype and prognosis].
Lu JB; Li XQ; Zhang PH; Zhou XY; Zhang TM; Li XM; Zhu XZ
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):470-3. PubMed ID: 17845761
[TBL] [Abstract][Full Text] [Related]
76. Clinicopathological Analysis of 320 Cases of Diffuse Large B-cell Lymphoma Using the Hans Classifier.
Ichiki A; Carreras J; Miyaoka M; Kikuti YY; Jibiki T; Tazume K; Watanabe S; Sasao T; Obayashi Y; Onizuka M; Ohmachi K; Yoshiba F; Shirasugi Y; Ogawa Y; Kawada H; Nakamura N; Ando K
J Clin Exp Hematop; 2017; 57(2):54-63. PubMed ID: 29021515
[TBL] [Abstract][Full Text] [Related]
77. Gene expression profiling of diffuse large B-Cell lymphomas supervised by CD5 expression.
Miyazaki K; Yamaguchi M; Imai H; Kobayashi K; Tamaru S; Kobayashi T; Shiku H; Katayama N
Int J Hematol; 2015 Aug; 102(2):188-94. PubMed ID: 26009281
[TBL] [Abstract][Full Text] [Related]
78. Low HIP1R mRNA and protein expression are associated with worse survival in diffuse large B-cell lymphoma patients treated with R-CHOP.
Wong KK; Ch'ng ES; Loo SK; Husin A; Muruzabal MA; Møller MB; Pedersen LM; Pomposo MP; Gaafar A; Banham AH; Green TM; Lawrie CH
Exp Mol Pathol; 2015 Dec; 99(3):537-45. PubMed ID: 26341140
[TBL] [Abstract][Full Text] [Related]
79. CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: a matched case-control analysis in a single institution.
Li YJ; Li ZM; Rao HL; Xia Y; Huang HQ; Xia ZJ; Li S; Li WY; Jiang WQ
J Transl Med; 2012 May; 10():84. PubMed ID: 22554077
[TBL] [Abstract][Full Text] [Related]
80. Diffuse large B cell lymphoma CD5-positive arising in an immune deficiency and immune dysregulation setting: A case report and brief review of the literature.
Cristian M; Baz RA; Stoica AG; Așchie M; Ghinea MM; Deacu M; Boșoteanu M; Mitroi AF; Dobrin N; Iordache IE; Bălțătescu GI
Medicine (Baltimore); 2023 Feb; 102(8):e33083. PubMed ID: 36827036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]